This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): VT122, etodolac/propranolol
Description: VT-122 is an oral, fixed dose combination of propranolol, a non-selective beta adrenergic receptor blocker, and etodolac, a COX1/2 enzyme inhibitor. These drugs were chosen based on the results of a cancer cachexia disease model that predicted blocking systemic inflammation would reverse the wasting process. While etodolac targets key inflammatory pathways in the tumor, liver and immune system, propranolol suppresses autonomic nervous system activation and excess catecholamine release.
Each day of therapy consists of four doses (capsules) each containing propranolol and etodolac. The pattern of administration during the day is designed to match the diurnal pattern in the change in blood pressure and heart rate as controlled by the autonomic nervous system. In addition, the company sought to optimize the impact on the pulmonary system, sleep and pain with the prescribed dose.
Additional information available to subscribers only: